Related Experiment Video
Updated: Apr 21, 2026
Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
Published on: October 2, 2014
[Expression and significance of HSP90 in plasma of patients with multiple myeloma]
Bin-Bin Zou1, Ning-Hong Guo1, Qing-Zhi Shi1
1Department of Hematology, The Second Affiliated Hospital,Nanchang University, Nanchang 330006,Jiangxi Province, China.
Abstract:
This study was purposed to investigate the expression of heat shock protein 90 (HSP90) in peripheral blood plasma of patients with multipl myeloma (MM), and to explore its possible role in the pathogenesis of MM, and its relationship with treatment, prognosis and the outcome of patients. The peripheral blood samples from 58 patients with MM and 20 healthy volunteers were collected. The plasma concentration of HSP90 in patients and healthy volunteers was measured by ELISA. The results showed that the concentration of HSP90 in peripheral blood of patients with MM was significantly higher than that in the healthy volunteers [(32.398 ± 3.674) vs (25.762 ± 2.916) ng/ml] (P < 0.001). The concentration of HSP90 showed positively correlation with International Staging System(ISS) stage, therapeutic response, frequency of plasmocyte, globulin, immune globulin, M-protein, β2 micro-globulin, and light chain of MM patients (P < 0.05) ; while it showed little correlation with sex, age and type of MM patients (P > 0.05) . It is concluded that the HSP90 may be involved in the occurrence and development of MM. Detection of HSP90 in plasma would contribute to judge the clinical course, therapeutic efficacy and prognosis of MM patients.
Insights
Elevated heat shock protein 90 (HSP90) levels in the blood plasma of multiple myeloma (MM) patients suggest its involvement in disease progression. Higher HSP90 concentrations correlate with advanced MM stages and specific biomarkers.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Context:
- Multiple myeloma (MM) is a hematological malignancy characterized by uncontrolled plasma cell proliferation.
- Understanding the molecular mechanisms and biomarkers associated with MM pathogenesis is crucial for improving patient outcomes.
Purpose:
- To investigate the expression levels of heat shock protein 90 (HSP90) in the peripheral blood plasma of MM patients.
- To explore the relationship between HSP90 expression and MM pathogenesis, clinical staging, treatment response, and prognosis.
Summary:
- Plasma concentrations of HSP90 were significantly higher in MM patients compared to healthy volunteers.
- HSP90 levels positively correlated with International Staging System (ISS) stage, therapeutic response, plasmocyte frequency, globulin, immunoglobulin, M-protein, β2 microglobulin, and light chain levels.
- No significant correlation was found between HSP90 levels and patient sex, age, or MM subtype.
Impact:
- HSP90 may play a role in the occurrence and development of multiple myeloma.
- Plasma HSP90 detection could serve as a valuable tool for assessing clinical course, therapeutic efficacy, and prognosis in MM patients.
